Tyra Biosciences (NASDAQ:TYRA – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04), FiscalAI reports.
Here are the key takeaways from Tyra Biosciences’ conference call:
- Tyra Biosciences said its lead FGFR3 inhibitor dabogratinib is advancing into multiple late-stage opportunities across its “Dabo 3×3” strategy, with the company framing several programs as potentially first-in-class or best-in-class.
- For intermediate-risk NMIBC, management highlighted a large addressable market and said the August readout from SURF302 should provide a go/no-go signal for phase III, with the company targeting a 70% or better complete response rate plus strong tolerability.
- The company emphasized that dabogratinib could offer a major convenience advantage over current bladder-cancer treatments by replacing repeated procedures and intravesical therapies with a simple oral daily pill, which they believe could improve patient and physician adoption.
- Tyra reported it has dosed its first patient in UTUC and views this as a more straightforward path to approval; management suggested that even moderate response rates could drive strong uptake because physicians may prefer an oral option over kidney-removing or invasive local treatments.
- In achondroplasia, the company said it has cleared its fourth dose in the Safety Sentinel cohort and highlighted encouraging preclinical data suggesting FGFR3 selectivity could meaningfully improve growth-related outcomes, with the goal of best-in-class efficacy versus peers.
Tyra Biosciences Trading Up 3.8%
Tyra Biosciences stock traded up $1.31 during trading hours on Wednesday, reaching $36.18. 644,214 shares of the stock were exchanged, compared to its average volume of 960,318. Tyra Biosciences has a twelve month low of $8.75 and a twelve month high of $40.65. The company has a market cap of $2.15 billion, a P/E ratio of -18.00 and a beta of 0.79. The stock has a 50 day moving average of $36.06 and a two-hundred day moving average of $28.77.
Analyst Ratings Changes
View Our Latest Report on Tyra Biosciences
Insider Buying and Selling
In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This trade represents a 33.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.50% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Tyra Biosciences
Several hedge funds have recently bought and sold shares of TYRA. Millennium Management LLC increased its holdings in Tyra Biosciences by 28.2% in the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after buying an additional 89,024 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after purchasing an additional 13,896 shares during the last quarter. Woodline Partners LP bought a new position in shares of Tyra Biosciences in the 1st quarter valued at $931,000. Jane Street Group LLC acquired a new position in shares of Tyra Biosciences during the 1st quarter worth $324,000. Finally, Geode Capital Management LLC lifted its position in shares of Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after buying an additional 50,836 shares during the last quarter. 84.14% of the stock is owned by institutional investors.
Tyra Biosciences Company Profile
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
